Build­ing on suc­cess­ful PD-1 pact, Eli Lil­ly li­cens­es di­a­betes drug to Chi­nese part­ners at In­novent

6 years ago
Deals
China

Clear­side Bio­med­ical pre­dicts its uveitis drug will be re­ject­ed, af­ter FDA re­quests more da­ta

6 years ago
R&D
FDA+

GSK's Hal Bar­ron her­alds their sec­ond pos­i­tive piv­otal for cru­cial an­ti-BC­MA ther­a­py, point­ing to a push for quick ...

6 years ago
R&D

Biotech lead­ers ral­ly be­hind Chi­nese sci­en­tists in US, calls for 'mea­sured' poli­cies in wake of purges

6 years ago
China

Am­gen, Al­ler­gan biosim­i­lar of Roche's block­buster Rit­ux­an clears an­oth­er US piv­otal study 

6 years ago
R&D

BeiGene and Mus­tang nail down spe­cial FDA sta­tus for top drugs; Roche bags added cov­er­age for Hem­li­bra

6 years ago
News Briefing

Trump ad­min­is­tra­tion re­vives bid to get drug list prices on TV ads

6 years ago
FDA+

Get as much Spra­va­to as you can, Trump or­ders VA while sug­gest­ing J&J should of­fer it to vet­er­ans for free

6 years ago
Pharma

An em­bold­ened As­traZeneca splurges $95M on a pri­or­i­ty re­view vouch­er. Where do they need the FDA to hus­tle up?

6 years ago
R&D
Pharma

Ver­sant-backed Chi­nook gets a $65M launch round for its dis­cov­ery quest in a resur­gent kid­ney field

6 years ago
Startups
Discovery

Sir An­drew Dil­lon, NICE's first — and on­ly — chief ex­ec­u­tive to step down next year

6 years ago
People
Pharma

Eight weeks be­tween each HIV treat­ment? GSK notch­es PhI­II win as it chas­es OK for long-act­ing reg­i­men

6 years ago
R&D

Pris­on­er #87850-053 does not get to add drug de­vel­op­er to his list of cred­its

6 years ago
R&D

Finch grabs a $53M round de­signed to take their ‘break­through’ mi­cro­bio­me treat­ment through a po­ten­tial­ly piv­otal ...

6 years ago
Startups
FDA+

Vi­en­na-based vac­cine de­vel­op­er Themis signs pact with Mer­ck for 'block­buster in­di­ca­tion'

6 years ago
Deals
R&D

SEC calls out lit­tle Ther­a­peu­tic­sMD for its in­sid­er con­tacts with an­a­lysts to boost share price, then halt rout

6 years ago
FDA+

GSK sub­mits its first ap­pli­ca­tion for dapro­du­s­tat in Japan; Two drug­mak­ers part with $15M to avoid opi­oid tri­al

6 years ago
News Briefing

MD­MA, now in Phase III, shows promise as a PTSD treat­ment

6 years ago
R&D

Pfiz­er is mak­ing a $500M state­ment to­day: Here’s how you be­come a lead play­er in the boom­ing gene ther­a­py sec­tor

6 years ago
R&D

MHRA to land a new in­ter­im chief ex­ec­u­tive ahead of Brex­it

6 years ago
People

[Video] Putting the AI in R&D — with Badhri Srini­vasan, Tony Wood, Rosana Kapeller, Hugo Ceule­mans, Saurabh Sa­ha ...

6 years ago
AI

Cowen, Per­cep­tive lead $79.5M Se­ries B for 's­tand­out' biotech shep­herd­ing on­colyt­ic virus to clin­ic

6 years ago
Financing

Fu­til­i­ty analy­sis au­gurs de­feat in piv­otal tri­al test­ing of Nu­Cana's lead drug in metasta­t­ic pan­cre­at­ic can­cer

6 years ago
R&D

As­traZeneca’s Imfinzi/treme com­bo strikes out — again — in lung can­cer. Is it time for last rites?

6 years ago
R&D
Pharma
First page Previous page 920921922923924925926 Next page Last page
A service from the Financial Times